THE QUESTION ON DPD: DETERMINANT PATIENT'S DATA?
A. C. Tralongo, G. Buccafusca, S. G. Rametta
Vol.4 (2019), issue 2, pag. 1 - 3
| Received | 25/06/2019 |
| Accepted | 27/08/2019 |
| Published | 07/10/2019 |
| Review by | Single-blind |
ABSTRACT
5- uorouracil infusion or capecitabine administration represent one of the most used chemotherapeutic drugs, especially in the treatment of colorectal cancer. Because of genetic alterations on speci c genes, involved in the metabolism of these drugs, in particular localized in dihydropyrimidine dehydrogenase (DYPD) gene, a minority of the patients develops severe toxicities, sometimes fatal. Many diagnostic tests exist to nd the subset of patients potentially more exposed at adverse events during the uoropyrimidine-based therapy. The cost per life-year gained (QALY) through the screening on these genetic mutations is proportionate to the tests routinely used in other similar clinical situations. The genetic screening approach should be considered the best strategy to treat patients with uoropyrimidine-based therapy.